TICKERNERD
Menu
OGNOGNHealthcare · Drug Manufacturers - General

OGN Stock Forecast: Organon & Co. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$14
0.00% on the day

The 5 Wall Street analysts covering Organon & Co. hold a median 12-month price target of $12 — -16.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 15 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$3.6B
Ticker Nerd rank
84 / 100
Median analyst target
$12
Analysts covering
5
Total return, dividends reinvested
1W
+0.9%
1M
+1.6%
YTD
+92.1%
1Y
+47.4%
From 52W high
0.0%
From 52W low
+141.1%
$6
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Organon & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Issuance
80
Momentum
77
Accruals
75
Quality
73
Revisions
64
Volatility
49
Growth
32
Size
29

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6$8$10$12$14Oct 25Jan 26Apr 26Jul 26OGNHigh $14Median $12Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
0 Buy4 Hold1 Sell
Low $8Median $12High $14

The green dot is the last close — the median target sits −16.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Apr 2026BNP ParibasDowngradeNeutral$12 → $14
28 Apr 2026Piper SandlerUpgradeNeutral$5.00 → $14
24 Feb 2026BarclaysMaintainsUnderweight—
9 Dec 2025BarclaysInitiatesUnderweight—
11 Nov 2025JP MorganMaintainsUnderweight—
11 Nov 2025Morgan StanleyMaintainsEqual-Weight—
15 May 2025Piper SandlerMaintainsOverweight—
5 May 2025Morgan StanleyMaintainsEqual-Weight—
9 Apr 2025Morgan StanleyMaintainsEqual-Weight—
14 Feb 2025BarclaysMaintainsOverweight—
14 Feb 2025Morgan StanleyMaintainsEqual-Weight—
6 Sept 2024JP MorganDowngradeUnderweight—
6 May 2024Goldman SachsMaintainsNeutral—
3 May 2024Goldman SachsMaintainsNeutral—
29 Apr 2024Piper SandlerMaintainsOverweight—
20 Feb 2024Goldman SachsMaintainsNeutral—
22 Nov 2023Piper SandlerMaintainsOverweight—
3 Nov 2023Goldman SachsDowngradeNeutral—
25 Oct 2023Piper SandlerMaintainsOverweight—
11 Oct 2023Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+4.4%
Analysts raising
0
Analysts cutting
0
Fundamentals

Organon & Co. (OGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.6×

Cheaper than 43% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
3.6×

Cheaper than 30% of US stocks

EV / EBITDA
7.0×

Cheaper than 48% of US stocks

Growth & margins
Revenue growth (YoY)
−2.3%

Higher than 24% of US stocks

Earnings growth (YoY)
−25.5%

Higher than 17% of US stocks

Gross margin
54.4%

Higher than 68% of US stocks

Operating margin
20.7%

Higher than 80% of US stocks

Net margin
3.4%

Higher than 56% of US stocks

Returns & dividend
Return on equity
24.0%

Higher than 85% of US stocks

Return on assets
5.7%

Higher than 80% of US stocks

Dividend yield
0.6%

Higher than 12% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
OGNOrganon & Co.$3.6B
84
BIIBBiogen, Inc.$30.8B
71
HTFLHeartFlow, Inc.*$3.6B
39
RCUSArcus Biosciences, Inc.*$3.6B
60
NHCNational HealthCare Corp.*$3.5B
67
OPCHOption Care Health, Inc.*$3.7B
81
DNLIDenali Therapeutics, Inc.*$3.8B
64

* Nearest Healthcare names by size — few drug manufacturers - general companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Organon & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OGN news & analysis

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Business Wire · 11 Aug 2026positive

Organon has opened the REMS certification program for MIUDELLA, its hormone-free copper IUD, allowing healthcare providers, settings, and pharmacies to begin certification ahead of the product's anticipated commercial launch.

Why it matters — The REMS program launch signals that MIUDELLA is moving closer to market availability, which could expand Organon's women's health product portfolio and revenue stream.

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research compared Organon's Q2 2026 revenue and EPS against Wall Street estimates and year-ago figures, noting that headline numbers don't tell the full story of the quarter's performance.

Why it matters — Investors tracking Organon would care about how key operational metrics stack up against analyst expectations and prior-year results for a clearer picture of business trends beyond just revenue and earnings.

Organon (OGN) Lags Q2 Earnings Estimates

Zacks Investment Research · 31 July 2026negative

Organon reported second-quarter earnings of $0.85 per share, falling short of the Zacks Consensus Estimate of $0.87 per share and down from $1.00 per share in the same quarter last year.

Why it matters — The earnings miss and year-over-year decline may signal weaker-than-expected near-term financial performance for Organon.

Organon Announces Quarterly Dividend

Business Wire · 31 July 2026neutral

Organon's Board of Directors declared a quarterly dividend of $0.02 per share, payable on September 10, 2026, to stockholders of record as of August 14, 2026.

Why it matters — The declaration of a quarterly dividend provides income-focused shareholders with a predictable return on their investment, reinforcing Organon's commitment to returning capital to stockholders.

FAQ

Frequently asked questions about OGN stock

What is the OGN stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Organon & Co. have a median 12-month price target of $12, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OGN stock a buy right now?

Of the 5 analysts covering Organon & Co., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Organon & Co. 84 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OGN?

As at 15 Aug 2026, Organon & Co. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will OGN stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -16.2% from the last close, and Ticker Nerd's factor model ranks Organon & Co. 84 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OGN stock forecast for 2030?

No analyst covering Organon & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.

How has OGN stock performed over the past year?

Organon & Co. returned +47.4% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Organon & Co. do?

Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies.

What is the latest news on OGN?

The most recent item we track (Business Wire, 11 Aug 2026): "Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability". Organon has opened the REMS certification program for MIUDELLA, its hormone-free copper IUD, allowing healthcare providers, settings, and pharmacies to begin certification ahead of the product's anticipated commercial launch.

Company

About Organon & Co.

Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology, and chronic disease management. The company offers products such as contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, alongside a range of mature branded medicines for pain, respiratory conditions, and cardiovascular disorders. Organon & Co. operates across major geographies, with significant presence in Europe, Canada, the United States, Asia Pacific, and Japan. It emphasizes research and development to advance therapies in women’s health and biosimilars, while maintaining a strong lineup of established products that provide reliable treatment options worldwide. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. plays a vital role in the pharmaceutical sector by bridging innovation with accessible healthcare solutions for diverse patient populations.

CEO Mr. Kevin Ali · 10,000 employees · United States · https://www.organon.com